bioRxiv Science⌕ Search

Biology subjects

Sekhon, S.

Publications and source records attributed to Sekhon, S..

2 recordsLinked to original sources

A multi-modal cell-free RNA language model for liquid biopsy applications

Cell-free RNA (cfRNA) profiling has emerged as a powerful tool for non-invasive disease detection, but its application is limited by data sparsity and complexity, especially in settings with constrained sample availability. We introduce Exai-1, a multi-modal, transformer-based generative foundation model that integrates RNA sequence embeddings with cfRNA abundance data to capture biologically meaningful representations of circulating RNAs. By leveraging both sequence and expression modalities, Exai-1 captures a biologically meaningful latent structure of cfRNA profiles. Pre-trained on over 306 billion tokens from 8,339 samples, Exai-1 enhances signal fidelity, reduces technical noise, and improves disease detection by generating synthetic cfRNA profiles. We show that self-attention and variational inference are particularly important for preservation of biological signals and contextual relationships. Additionally, Exai-1 facilitates cross-biofluid translation and assay compatibility through disentangling biological signals from confounders. By uniting sequence-informed embeddings with cfRNA expression patterns, Exai-1 establishes a transfer learning foundation for liquid biopsy, offering a scalable and adaptable framework for next-generation cfRNA-based diagnostics.

bioinformatics↗

Transcriptomic profiling of plaque psoriasis and cutaneous T cell subsets during treatment with secukinumab

The IL17A inhibitor secukinumab is efficacious for the treatment of psoriasis. In order to define its mechanism of action, it is important to understand its impact on psoriatic whole skin tissue as well as specific skin-resident immune cell populations such as T lymphocytes. In this study, we treated 15 moderate-to-severe plaque psoriasis patients with secukinumab and characterized the longitudinal transcriptomic changes of whole lesional skin tissue and cutaneous CD4+ T effector cells (Teffs), CD4+ T regulatory cells (Tregs), and CD8+ T effector cells during 12 weeks of treatment. Secukinumab was clinically effective, with 100%, 47%, and 27% of patients in the study achieving PASI75, PASI90, and PASI100 by week 12, respectively. At baseline prior to treatment, we observed that IL17A overexpression predominates in psoriatic CD8+ T cells rather than Teffs, supporting the importance of IL-17-secreting CD8+ T cells (Tc17) compared to IL-17-secreting CD4+ T cells (Th17) cells in the pathogenesis of psoriasis. Although secukinumab targets only IL17A, we observed rapid reduction of IL17A, IL17F, IL23A, IL23R, and IFNG expression in lesional skin as soon as 2 weeks after initiation of treatment and normalization of expression by week 12. Secukinumab treatment resulted in resolution of 89-97% of psoriasis-associated expression differences in both bulk tissue and T cell subsets by week 12 of treatment. Overall, secukinumab appears to rapidly reverse many of the molecular hallmarks of psoriasis.

genomics↗